Neuro-oncology: Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

1. Current treatments for non-small cell lung cancer.Frontiers in oncology · 2022
   Review
2. Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging.Neuro-oncology · 2017
   Article
3. The Microenvironmental Landscape of Brain Tumors.Cancer cell · 2017
   Review
4. An overview of neuro-oncology research and practice in Iran, three years with the NOSC initiative.International journal of clinical and experimental medicine · 2015
   Article

Corrections and comments

• Comment on
  A randomized trial of bevacizumab for newly diagnosed glioblastoma.2014
• Comment on
  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.2014

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as